



Wellpoint New Jersey

P. O. Box 62509
Virginia Beach, VA 24466-2509

<Date>

<Parent or Guardian of>

<Member Name>

<Member Address>

<Member City, State ZIP>

Dear Member or Parent/Guardian of <Member Name>:

We have important drug recall information about your prescription for Clonidine Transdermal System.

Our records show that you may have recently filled a prescription for this drug.

On April 13, 2026, the United States Food and Drug Administration (FDA) issued a Class II recall of certain lot numbers of Clonidine Transdermal System distributed by Actavis Pharma Inc.

The recalling firm, Teva Pharmaceuticals USA, Inc., issued this recall due to CGMP Deviations: use of an unapproved raw material.

Talk to your doctor before you stop taking any medication. Stopping a drug without a replacement could have health risks. Your doctor can talk to you about other options that are right for you.

What you need to do next:

Although the recalling firm doesn't need any action on your part, if you have questions or concerns about this recall, contact the recalling firm.

wellpoint.com/nj/medicaid

1090799NJMESWLP 04/26

OMHC# 078-25-59

105-CNMCD26046WLPNJ 042226





We're here to help

If you have questions about the recall, please call Teva Medical Information at 1-888-838-2872, option 3, then option 4, Monday through Friday, 9:00 am to 5:00 pm (ET) or email at druginfo@tevapharm.com. You can contact the FDA toll-free at **888-INFO-FDA (888-463-6332)** or visit fda.gov for more information.

You can also call your doctor or pharmacist if you have questions about the drug or about this letter. If you have questions about your prescription drug benefits, please call Pharmacy Member Services at the phone number on your member ID card (TTY users can call **711**).

Sincerely,

Your Wellpoint service team

Enclosures: Language assistance sheet
Nondiscrimination notice

This information is provided for educational purposes only and should not be considered medical advice. Talk to your physician for specific treatment options and recommendations best suited for you and before beginning any lifestyle program.



Product: Clonidine Transdermal System USP, 0.1 mg/day
Carton

NDC: 00591-3508-04

Lot number/Expiration date: 100060315 exp. 04/2026,
100068644 exp. 01/2027

Product: Clonidine Transdermal System, USP, 0.1 mg/day
Pouch

NDC: 00591-3508-54

Lot number/Expiration date: 100060315 exp. 04/2026,
100068644 exp. 01/2027

Product: Clonidine Transdermal System, USP, 0.2 mg/day
Carton

NDC: 00591-3509-04

Lot number/Expiration date: 100060002 exp. 07/2026,
100066802 exp. 05/2027

Product: Clonidine Transdermal System, USP, 0.2 mg/day
Pouch

NDC: 00591-3509-54

Lot number/Expiration date: 100060002 exp. 07/2026,
100066802 exp. 05/2027

Product: Clonidine Transdermal System, USP, 0.3 mg/day
Carton

NDC: 00591-3510-04

Lot number/Expiration date: 100053892 exp. 04/2026,
100057899 exp. 05/2026, 100062704 exp. 02/2027

Product: Clonidine Transdermal System, USP, 0.3 mg/day
Pouch

NDC: 00591-3510-54

Lot number/Expiration date: 100053892 exp. 04/2026,
100057899 exp. 05/2026, 100062704 exp. 02/2027

wellpoint.com/nj/medicaid

1090799NJMESWLP 04/26

OMHC# 078-25-59

105-CNMCD26046WLPNJ 042226



Wellpoint New Jersey

P. O. Box 62509

Virginia Beach, VA 24466-2509

<Date>

<Padre o tutor de>

<Member Name>

<Member Address>

<Member City, State ZIP>

Estimado/a miembro o padre/tutor de <Member Name>:

Tenemos información importante del retiro de medicamento sobre su receta para sistema transdérmico de clonidina.

Nuestros registros muestran que usted tal vez ha surtido recientemente una receta de este medicamento.

El 13 de abril de 2026, la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos emitió un retiro Clase II de determinados números de lote de sistema transdérmico de clonidina distribuidos por Actavis Pharma Inc.

La empresa que retiró el medicamento, Teva Pharmaceuticals USA, Inc., emitió este retiro debido a desviaciones en las buenas prácticas de fabricación actuales (CGMP): uso de un material crudo no aprobado.

Hable con su médico antes de dejar de tomar cualquier medicamento. Dejar de tomar un medicamento sin un reemplazo podría tener riesgos para la salud. Su médico puede hablar con usted sobre otras opciones que sean adecuadas para usted.

Qué debe hacer a continuación:

Aunque la empresa que retiró el medicamento no necesita ninguna acción de su parte, si tiene preguntas o dudas sobre este retiro, contacte a la empresa que retiró el medicamento.

Estamos a su disposición para ayudar

Si tiene preguntas sobre el retiro, llame a Teva Medical Information al 1-888-838-2872, opción 3, luego, opción 4, de lunes a viernes, de 09:00 a. m. a 05:00 p. m. (hora del



Producto: sistema transdérmico de clonidina, USP, caja de 0.2mg/día

NDC: 00591-3509-04

Número de lote/fecha de vencimiento: 100060002 vto. 07/2026, 100066802 vto. 05/2027

Producto: sistema transdérmico de clonidina, USP, bolsa de 0.2 mg/día

NDC: 00591-3509-54

Número de lote/fecha de vencimiento: 100060002 vto. 07/2026, 100066802 vto. 05/2027

Producto: sistema transdérmico de clonidina, USP, caja de 0.3 mg/día

NDC: 00591-3510-04

Número de lote/fecha de vencimiento: 100053892 vto. 04/2026, 100057899 vto. 05/2026, 00062704 vto. 02/2027

Producto: sistema transdérmico de clonidina, USP, caja de 0.3 mg/día

NDC: 00591-3510-54

Número de lote/fecha de vencimiento: 100053892 vto. 04/2026, 100057899 vto. 05/2026, 100062704 vto. 02/2027